Sign up Australia
Proactive Investors - Run By Investors For Investors

Actinogen Medical Ltd to enhance safety profile of Alzheimer’s drug study

Actinogen Medical Ltd to enhance safety profile of Alzheimer’s drug study

Actinogen Medical Ltd (ASX:ACW) is making progress in its Phase II clinical trial of its promising new Alzheimer’s drug Xanamem after discussions with the U.S. FDA.

The company is seeking FDA approval under an Investigational New Drug (IND) for the Phase II study of the drug.

The company is interacting with the U.S. FDA to enhance the safety profile of XanADu, their pivotal global Phase II clinical trial investigating Xanamem.

An enhanced protocol will be detemined with both Australian and U.K. regulators and hospital sites, with patients expected to be enrolled in the second half of 2016.

Importantly, a U.S. focused study and protocol design will allow for broader value creation, as the U.S. is the largest market for Alzheimer’s drugs.

Xanamem has been specifically designed to inhibit the excess production of cortisol, the ‘stress hormone’ in the brain.

Recent global research has demonstrated that excess cortisol is associated with cognitive decline and neurotoxicity in the brain, which are the hallmarks of Alzheimer’s disease.

In 2015 the total estimated global cost of treating Alzheimer’s was close to US$1 trillion.

The potential upside for a successful drug is significant, which has helped Actinogen share price almost double during the last six months.

The phase II study is fully funded through to completion with $6.8 million cash as on 31 March 2016.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.





Register here to be notified of future ACW Company articles
View full ACW profile View Profile

Actinogen Medical Ltd Timeline

Newswire
December 30 2016

Related Articles

biotechLatest.jpg
March 28 2017
2017 is going to be quite action packed we believe we have positioned the company for when RNA interference transforms from a technology to its promise of a new class of therapeutics - boss Ali Mortazavi.
Cancer cells
September 05 2017
In an initiation note on the company, finnCap’s analysts noted that ANGLE is focused on the development of Parsortix, an instrument platform with recurring revenues designed to isolate and harvest rare circulating tumour cells from a patient’s blood sample
scientist looking through a microscope
November 01 2017
As of March, ReNeuron had £53mln in cash equivalents but its market value is not too much above that....

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use